Comparison of metformin, pioglitazone and vitamin E on nonalcoholic fatty liver disease
Phase 3
- Conditions
- onalcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2013071313069N2
- Lead Sponsor
- Vice chancellor for research, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 93
Inclusion Criteria
Age above 18 year and Non-alcoholic fatty liver disease alone with negative hepatitis serology
Exclusion criteria: clinical manifestation of liver disease, icter, steroid and alcohol use, diabetes, pregnancy, hypothyroidism, renal failure.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzymes, Blood sugar, Insulin. Timepoint: Before and 12 weeks after treatment. Method of measurement: Laboratory assessment (ELISA).
- Secondary Outcome Measures
Name Time Method iver echo pattern. Timepoint: Before and 12 weeks after treatment. Method of measurement: Sonographic assessment.